Search Results

1. Prescription Medications to Treat Overweight & Obesity

   /health-information/weight-management/prescription-medications-treat-overweight-obesity

   management medications for children ages 12 and older: orlistat (Xenical),2 liraglutide (Saxenda),3 phentermine-topiramate (Qsymia),4 and semaglutide (Wegovy...

2. What’s New in Medications for Weight Management for People with Diabetes

   /health-information/professionals/diabetes-discoveries-practice/new-in-medications-for-weight-management

   The diabetes medication semaglutide was recently approved to treat obesity, and other potentially effective obesity medications are in the pipeline...

3. Clinical Trials | Liver & Energy Metabolism Section

   /research-funding/at-niddk/labs-branches/liver-diseases-branch/liver-energy-metabolism-section/clinical-trials

   Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) Background: In non-alcoholic...

4. Clinical Trials | Clinical Research Section

   /research-funding/at-niddk/labs-branches/liver-diseases-branch/clinical-research-section/clinical-trials

   the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates...

5. Publications | Neuromodulation & Motivation Section

   /research-funding/at-niddk/labs-branches/diabetes-endocrinology-obesity-branch/neuromodulation-and-motivation-section/publications

   Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons. Gao C, Geneve IC, Rodriguez-Gonzalez S, Li C...

6. Making New Connections to Address the Silent Epidemic of Nonalcoholic Fatty Liver Disease

   /news/archive/2024/making-new-connections-address-silent-epidemic-nonalcoholic-fatty-liver-disease

   based drugs approved by the FDA for treating type 2 diabetes and obesity, such as semaglutide. These drugs work through a protein called the glucagon-like...

7. Publications | Andrew Lutas, Ph.D., Stadtman Tenure-Track Investigator

   /about-niddk/staff-directory/biography/lutas-andrew/publications

   Biology Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons. Gao C, Geneve IC, Rodriguez-Gonzalez S, Li C...

8. NIH Obesity Research Task Force Symposium: Clinical Research Strategies for Sustainable Obesity Care

   /news/meetings-workshops/2025/clinical-research-strategies-sustainable-obesity-care

   Purpose Highly effective anti-obesity medications (AOMs), including semaglutide and tirzepatide, can produce mean weight loss of greater than 15...

9. Lab Members | Section on Motivational Processes Underlying Appetite

   /research-funding/at-niddk/labs-branches/diabetes-endocrinology-obesity-branch/motivational-processes-underlying-appetite-section/members

   fellow. Dr. Gao was awarded the NIGMS PRAT (Fi2) fellowship in 2024. Her current research investigates how anti-obesity medications such as semaglutide...

10. DDP Blog: Best of 2022

    /health-information/professionals/diabetes-discoveries-practice/best-ddp-blog-2022

    discusses the critical need for effective ways to treat and manage weight for people with diabetes. She also describes semaglutide and other new medications...